2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 261

Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience
Abstract Number: 1427

Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia
Abstract Number: 2112

Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Abstract Number: 2827

Analysis of HLA-B27 Transgenic Rats Reveals Specific Gut Transcriptome and Microbiome Signatures Associated with Inflammation
Abstract Number: 33

Analysis of Incidence Rates of Pulmonary Embolism in the Rheumatoid Arthritis Population Compared with the Non-Rheumatoid Arthritis Population
Abstract Number: 2656

Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Abstract Number: 2916

Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis
Abstract Number: 1120

Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)
Abstract Number: 105

Analysis of the Association of PTGER4 Gene Variants with Radiological Joint Damage in Rheumatoid Arthritis
Abstract Number: 881

ANCA Associated Vasculitis with Hypocomplementemia Has More Diffuse Alveolar Hemorrhage and a Poor Prognosis
Abstract Number: 861

ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?
Abstract Number: 1082

ANCA-Negative and Myeloperoxidase-ANCA-Positive Patients with Granulomatosis with Polyangiitis: Clinical Manifestations and Risk of Relapse
Abstract Number: 282

Angiogenesis in Fasciitis Associated with Dermatomyositis
Abstract Number: 3220

Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Abstract Number: 3223

Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].